Keep Us Strong WikiLeaks logo

Currently released so far... 251287 / 251,287

Articles

Browse latest releases

Browse by creation date

Browse by origin

A B C D F G H I J K L M N O P Q R S T U V W Y Z

Browse by tag

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
AEMR ASEC AMGT AE AS AMED AVIAN AU AF AORC AGENDA AO AR AM APER AFIN ATRN AJ ABUD ARABL AL AG AODE ALOW ADANA AADP AND APECO ACABQ ASEAN AA AFFAIRS AID AGR AY AGS AFSI AGOA AMB ARF ANET ASCH ACOA AFLU AFSN AMEX AFDB ABLD AESC AFGHANISTAN AINF AVIATION ARR ARSO ANDREW ASSEMBLY AIDS APRC ASSK ADCO ASIG AC AZ APEC AFINM ADB AP ACOTA ASEX ACKM ASUP ANTITERRORISM ADPM AINR ARABLEAGUE AGAO AORG AMTC AIN ACCOUNT ASECAFINGMGRIZOREPTU AIDAC AINT ARCH AMGTKSUP ALAMI AMCHAMS ALJAZEERA AVIANFLU AORD AOREC ALIREZA AOMS AMGMT ABDALLAH AORCAE AHMED ACCELERATED AUC ALZUGUREN ANGEL AORL ASECIR AMG AMBASSADOR AEMRASECCASCKFLOMARRPRELPINRAMGTJMXL ADM ASES ABMC AER AMER ASE AMGTHA ARNOLDFREDERICK AOPC ACS AFL AEGR ASED AFPREL AGRI AMCHAM ARNOLD AN ANATO AME APERTH ASECSI AT ACDA ASEDC AIT AMERICA AMLB AMGE ACTION AGMT AFINIZ ASECVE ADRC ABER AGIT APCS AEMED ARABBL ARC ASO AIAG ACEC ASR ASECM ARG AEC ABT ADIP ADCP ANARCHISTS AORCUN AOWC ASJA AALC AX AROC ARM AGENCIES ALBE AK AZE AOPR AREP AMIA ASCE ALANAZI ABDULRAHMEN ABDULHADI AINFCY ARMS ASECEFINKCRMKPAOPTERKHLSAEMRNS AGRICULTURE AFPK AOCR ALEXANDER ATRD ATFN ABLG AORCD AFGHAN ARAS AORCYM AVERY ALVAREZ ACBAQ ALOWAR ANTOINE ABLDG ALAB AMERICAS AFAF ASECAFIN ASEK ASCC AMCT AMGTATK AMT APDC AEMRS ASECE AFSA ATRA ARTICLE ARENA AISG AEMRBC AFR AEIR ASECAF AFARI AMPR ASPA ASOC ANTONIO AORCL ASECARP APRM AUSTRALIAGROUP ASEG AFOR AEAID AMEDI ASECTH ASIC AFDIN AGUIRRE AUNR ASFC AOIC ANTXON ASA ASECCASC ALI AORCEUNPREFPRELSMIGBN ASECKHLS ASSSEMBLY ASECVZ AI ASECPGOV ASIR ASCEC ASAC ARAB AIEA ADMIRAL AUSGR AQ AMTG ARRMZY ANC APR AMAT AIHRC AFU ADEL AECL ACAO AMEMR ADEP AV AW AOR ALL ALOUNI AORCUNGA ALNEA ASC AORCO ARMITAGE AGENGA AGRIC AEM ACOAAMGT AGUILAR AFPHUM AMEDCASCKFLO AFZAL AAA ATPDEA ASECPHUM ASECKFRDCVISKIRFPHUMSMIGEG
ETRD ETTC EU ECON EFIN EAGR EAID ELAB EINV ENIV ENRG EPET EZ ELTN ELECTIONS ECPS ET ER EG EUN EIND ECONOMICS EMIN ECIN EINT EWWT EAIR EN ENGR ES EI ETMIN EL EPA EARG EFIS ECONOMY EC EK ELAM ECONOMIC EAR ESDP ECCP ELN EUM EUMEM ECA EAP ELEC ECOWAS EFTA EXIM ETTD EDRC ECOSOC ECPSN ENVIRONMENT ECO EMAIL ECTRD EREL EDU ENERG ENERGY ENVR ETRAD EAC EXTERNAL EFIC ECIP ERTD EUC ENRGMO EINZ ESTH ECCT EAGER ECPN ELNT ERD EGEN ETRN EIVN ETDR EXEC EIAD EIAR EVN EPRT ETTF ENGY EAIDCIN EXPORT ETRC ESA EIB EAPC EPIT ESOCI ETRB EINDQTRD ENRC EGOV ECLAC EUR ELF ETEL ENRGUA EVIN EARI ESCAP EID ERIN ELAN ENVT EDEV EWWY EXBS ECOM EV ELNTECON ECE ETRDGK EPETEIND ESCI ETRDAORC EAIDETRD ETTR EMS EAGRECONEINVPGOVBN EBRD EUREM ERGR EAGRBN EAUD EFI ETRDEINVECINPGOVCS EPEC ETRO ENRGY EGAR ESSO EGAD ENV ENER EAIDXMXAXBXFFR ELA EET EINVETRD EETC EIDN ERGY ETRDPGOV EING EMINCG EINVECON EURM EEC EICN EINO EPSC ELAP ELABPGOVBN EE ESPS ETRA ECONETRDBESPAR ERICKSON EEOC EVENTS EPIN EB ECUN EPWR ENG EX EH EAIDAR EAIS ELBA EPETUN ETRDEIQ EENV ECPC ETRP ECONENRG EUEAID EWT EEB EAIDNI ESENV EADM ECN ENRGKNNP ETAD ETR ECONETRDEAGRJA ETRG ETER EDUC EITC EBUD EAIF EBEXP EAIDS EITI EGOVSY EFQ ECOQKPKO ETRGY ESF EUE EAIC EPGOV ENFR EAGRE ENRD EINTECPS EAVI ETC ETCC EIAID EAIDAF EAGREAIDPGOVPRELBN EAOD ETRDA EURN EASS EINVA EAIDRW EON ECOR EPREL EGPHUM ELTM ECOS EINN ENNP EUPGOV EAGRTR ECONCS ETIO ETRDGR EAIDB EISNAR EIFN ESPINOSA EAIDASEC ELIN EWTR EMED ETFN ETT EADI EPTER ELDIN EINVEFIN ESS ENRGIZ EQRD ESOC ETRDECD ECINECONCS EAIT ECONEAIR ECONEFIN EUNJ ENRGKNNPMNUCPARMPRELNPTIAEAJMXL ELAD EFIM ETIC EFND EFN ETLN ENGRD EWRG ETA EIN EAIRECONRP EXIMOPIC ERA ENRGJM ECONEGE ENVI ECHEVARRIA EMINETRD EAD ECONIZ EENG ELBR EWWC ELTD EAIDMG ETRK EIPR EISNLN ETEX EPTED EFINECONCS EPCS EAG ETRDKIPR ED EAIO ETRDEC ENRGPARMOTRASENVKGHGPGOVECONTSPLEAID ECONEINVEFINPGOVIZ ERNG EFINU EURFOR EWWI ELTNSNAR ETD EAIRASECCASCID EOXC ESTN EAIDAORC EAGRRP ETRDEMIN ELABPHUMSMIGKCRMBN ETRDEINVTINTCS EGHG EAIDPHUMPRELUG EAGRBTIOBEXPETRDBN EDA EPETPGOV ELAINE EUCOM EMW EFINECONEAIDUNGAGM ELB EINDETRD EMI ETRDECONWTOCS EINR ESTRADA EHUM EFNI ELABV ENR EMN EXO EWWTPRELPGOVMASSMARRBN EATO END EP EINVETC ECONEFINETRDPGOVEAGRPTERKTFNKCRMEAID ELTRN EIQ ETTW EAI ENGRG ETRED ENDURING ETTRD EAIDEGZ EOCN EINF EUPREL ENRL ECPO ENLT EEFIN EPPD ECOIN EUEAGR EISL EIDE ENRGSD EINVECONSENVCSJA EAIG ENTG EEPET EUNCH EPECO ETZ EPAT EPTE EAIRGM ETRDPREL EUNGRSISAFPKSYLESO ETTN EINVKSCA ESLCO EBMGT ENRGTRGYETRDBEXPBTIOSZ EFLU ELND EFINOECD EAIDHO EDUARDO ENEG ECONEINVETRDEFINELABETRDKTDBPGOVOPIC EFINTS ECONQH ENRGPREL EUNPHUM EINDIR EPE EMINECINECONSENVTBIONS EFINM ECRM EQ EWWTSP ECONPGOVBN
KFLO KPKO KDEM KFLU KTEX KMDR KPAO KCRM KIDE KN KNNP KG KMCA KZ KJUS KWBG KU KDMR KAWC KCOR KPAL KOMC KTDB KTIA KISL KHIV KHUM KTER KCFE KTFN KS KIRF KTIP KIRC KSCA KICA KIPR KPWR KWMN KE KGIC KGIT KSTC KACT KSEP KFRD KUNR KHLS KCRS KRVC KUWAIT KVPR KSRE KMPI KMRS KNRV KNEI KCIP KSEO KITA KDRG KV KSUM KCUL KPET KBCT KO KSEC KOLY KNAR KGHG KSAF KWNM KNUC KMNP KVIR KPOL KOCI KPIR KLIG KSAC KSTH KNPT KINL KPRP KRIM KICC KIFR KPRV KAWK KFIN KT KVRC KR KHDP KGOV KPOW KTBT KPMI KPOA KRIF KEDEM KFSC KY KGCC KATRINA KWAC KSPR KTBD KBIO KSCI KRCM KNNB KBNC KIMT KCSY KINR KRAD KMFO KCORR KW KDEMSOCI KNEP KFPC KEMPI KBTR KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG KNPP KTTB KTFIN KBTS KCOM KFTN KMOC KOR KDP KPOP KGHA KSLG KMCR KJUST KUM KMSG KHPD KREC KIPRTRD KPREL KEN KCSA KCRIM KGLB KAKA KWWT KUNP KCRN KISLPINR KLFU KUNC KEDU KCMA KREF KPAS KRKO KNNC KLHS KWAK KOC KAPO KTDD KOGL KLAP KECF KCRCM KNDP KSEAO KCIS KISM KREL KISR KISC KKPO KWCR KPFO KUS KX KWCI KRFD KWPG KTRD KH KLSO KEVIN KEANE KACW KWRF KNAO KETTC KTAO KWIR KVCORR KDEMGT KPLS KICT KWGB KIDS KSCS KIRP KSTCPL KDEN KLAB KFLOA KIND KMIG KPPAO KPRO KLEG KGKG KCUM KTTP KWPA KIIP KPEO KICR KNNA KMGT KCROM KMCC KLPM KNNPGM KSIA KSI KWWW KOMS KESS KMCAJO KWN KTDM KDCM KCM KVPRKHLS KENV KCCP KGCN KCEM KEMR KWMNKDEM KNNPPARM KDRM KWIM KJRE KAID KWMM KPAONZ KUAE KTFR KIF KNAP KPSC KSOCI KCWI KAUST KPIN KCHG KLBO KIRCOEXC KI KIRCHOFF KSTT KNPR KDRL KCFC KLTN KPAOKMDRKE KPALAOIS KESO KKOR KSMT KFTFN KTFM KDEMK KPKP KOCM KNN KISLSCUL KFRDSOCIRO KINT KRG KWMNSMIG KSTCC KPAOY KFOR KWPR KSEPCVIS KGIV KSEI KIL KWMNPHUMPRELKPAOZW KQ KEMS KHSL KTNF KPDD KANSOU KKIV KFCE KTTC KGH KNNNP KK KSCT KWNN KAWX KOMCSG KEIM KTSD KFIU KDTB KFGM KACP KWWMN KWAWC KSPA KGICKS KNUP KNNO KISLAO KTPN KSTS KPRM KPALPREL KPO KTLA KCRP KNMP KAWCK KCERS KDUM KEDM KTIALG KWUN KPTS KPEM KMEPI KAWL KHMN KCRO KCMR KPTD KCROR KMPT KTRF KSKN KMAC KUK KIRL KEM KSOC KBTC KOM KINP KDEMAF KTNBT KISK KRM KWBW KBWG KNNPMNUC KNOP KSUP KCOG KNET KWBC KESP KMRD KEBG KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG KPWG KOMCCO KRGY KNNF KPROG KJAN KFRED KPOKO KM KWMNCS KMPF KJWC KJU KSMIG KALR KRAL KDGOV KPA KCRMJA KCRI KAYLA KPGOV KRD KNNPCH KFEM KPRD KFAM KALM KIPRETRDKCRM KMPP KADM KRFR KMWN KWRG KTIAPARM KTIAEUN KRDP KLIP KDDEM KTIAIC KWKN KPAD KDM KRCS KWBGSY KEAI KIVP KPAOPREL KUNH KTSC KIPT KNP KJUSTH KGOR KEPREL KHSA KGHGHIV KNNR KOMH KRCIM KWPB KWIC KINF KPER KILS KA KNRG KCSI KFRP KLFLO KFE KNPPIS KQM KQRDQ KERG KPAOPHUM KSUMPHUM KVBL KARIM KOSOVO KNSD KUIR KWHG KWBGXF KWMNU KPBT KKNP KERF KCRT KVIS KWRC KVIP KTFS KMARR KDGR KPAI KDE KTCRE KMPIO KUNRAORC KHOURY KAWS KPAK KOEM KCGC KID KVRP KCPS KIVR KBDS KWOMN KIIC KTFNJA KARZAI KMVP KHJUS KPKOUNSC KMAR KIBL KUNA KSA KIS KJUSAF KDEV KPMO KHIB KIRD KOUYATE KIPRZ KBEM KPAM KDET KPPD KOSCE KJUSKUNR KICCPUR KRMS KWMNPREL KWMJN KREISLER KWM KDHS KRV KPOV KWMNCI KMPL KFLD KWWN KCVM KIMMITT KCASC KOMO KNATO KDDG KHGH KRF KSCAECON KWMEN KRIC
PREL PINR PGOV PHUM PTER PE PREF PARM PBTS PINS PHSA PK PL PM PNAT PHAS PO PROP PGOVE PA PU POLITICAL PPTER POL PALESTINIAN PHUN PIN PAMQ PPA PSEC POLM PBIO PSOE PDEM PAK PF PKAO PGOVPRELMARRMOPS PMIL PV POLITICS PRELS POLICY PRELHA PIRN PINT PGOG PERSONS PRC PEACE PROCESS PRELPGOV PROV PFOV PKK PRE PT PIRF PSI PRL PRELAF PROG PARMP PERL PUNE PREFA PP PGOB PUM PROTECTION PARTIES PRIL PEL PAGE PS PGO PCUL PLUM PIF PGOVENRGCVISMASSEAIDOPRCEWWTBN PMUC PCOR PAS PB PKO PY PKST PTR PRM POUS PRELIZ PGIC PHUMS PAL PNUC PLO PMOPS PHM PGOVBL PBK PELOSI PTE PGOVAU PNR PINSO PRO PLAB PREM PNIR PSOCI PBS PD PHUML PERURENA PKPA PVOV PMAR PHUMCF PUHM PHUH PRELPGOVETTCIRAE PRT PROPERTY PEPFAR PREI POLUN PAR PINSF PREFL PH PREC PPD PING PQL PINSCE PGV PREO PRELUN POV PGOVPHUM PINRES PRES PGOC PINO POTUS PTERE PRELKPAO PRGOV PETR PGOVEAGRKMCAKNARBN PPKO PARLIAMENT PEPR PMIG PTBS PACE PETER PMDL PVIP PKPO POLMIL PTEL PJUS PHUMNI PRELKPAOIZ PGOVPREL POGV PEREZ POWELL PMASS PDOV PARN PG PPOL PGIV PAIGH PBOV PETROL PGPV PGOVL POSTS PSO PRELEU PRELECON PHUMPINS PGOVKCMABN PQM PRELSP PRGO PATTY PRELPGOVEAIDECONEINVBEXPSCULOIIPBTIO PGVO PROTESTS PRELPLS PKFK PGOVEAIDUKNOSWGMHUCANLLHFRSPITNZ PARAGRAPH PRELGOV POG PTRD PTERM PBTSAG PHUMKPAL PRELPK PTERPGOV PAO PRIVATIZATION PSCE PPAO PGOVPRELPHUMPREFSMIGELABEAIDKCRMKWMN PARALYMPIC PRUM PKPRP PETERS PAHO PARMS PGREL PINV POINS PHUMPREL POREL PRELNL PHUMPGOV PGOVQL PLAN PRELL PARP PROVE PSOC PDD PRELNP PRELBR PKMN PGKV PUAS PRELTBIOBA PBTSEWWT PTERIS PGOVU PRELGG PHUMPRELPGOV PFOR PEPGOV PRELUNSC PRAM PICES PTERIZ PREK PRELEAGR PRELEUN PHUME PHU PHUMKCRS PRESL PRTER PGOF PARK PGOVSOCI PTERPREL PGOVEAID PGOVPHUMKPAO PINSKISL PREZ PGOVAF PARMEUN PECON PINL POGOV PGOVLO PIERRE PRELPHUM PGOVPZ PGOVKCRM PBST PKPAO PHUMHUPPS PGOVPOL PASS PPGOV PROGV PAGR PHALANAGE PARTY PRELID PGOVID PHUMR PHSAQ PINRAMGT PSA PRELM PRELMU PIA PINRPE PBTSRU PARMIR PEDRO PNUK PVPR PINOCHET PAARM PRFE PRELEIN PINF PCI PSEPC PGOVSU PRLE PDIP PHEM PRELB PORG PGGOC POLG POPDC PGOVPM PWMN PDRG PHUMK PINB PRELAL PRER PFIN PNRG PRED POLI PHUMBO PHYTRP PROLIFERATION PHARM PUOS PRHUM PUNR PENA PGOVREL PETRAEUS PGOVKDEM PGOVENRG PHUS PRESIDENT PTERKU PRELKSUMXABN PGOVSI PHUMQHA PKISL PIR PGOVZI PHUMIZNL PKNP PRELEVU PMIN PHIM PHUMBA PUBLIC PHAM PRELKPKO PMR PARTM PPREL PN PROL PDA PGOVECON PKBL PKEAID PERM PRELEZ PRELC PER PHJM PGOVPRELPINRBN PRFL PLN PWBG PNG PHUMA PGOR PHUMPTER POLINT PPEF PKPAL PNNL PMARR PAC PTIA PKDEM PAUL PREG PTERR PTERPRELPARMPGOVPBTSETTCEAIRELTNTC PRELJA POLS PI PNS PAREL PENV PTEROREP PGOVM PINER PBGT PHSAUNSC PTERDJ PRELEAID PARMIN PKIR PLEC PCRM PNET PARR PRELETRD PRELBN PINRTH PREJ PEACEKEEPINGFORCES PEMEX PRELZ PFLP PBPTS PTGOV PREVAL PRELSW PAUM PRF PHUMKDEM PATRICK PGOVKMCAPHUMBN PRELA PNUM PGGV PGOVSMIGKCRMKWMNPHUMCVISKFRDCA PBT PIND PTEP PTERKS PGOVJM PGOT PRELMARR PGOVCU PREV PREFF PRWL PET PROB PRELPHUMP PHUMAF PVTS PRELAFDB PSNR PGOVECONPRELBU PGOVZL PREP PHUMPRELBN PHSAPREL PARCA PGREV PGOVDO PGON PCON PODC PRELOV PHSAK PSHA PGOVGM PRELP POSCE PGOVPTER PHUMRU PINRHU PARMR PGOVTI PPEL PMAT PAN PANAM PGOVBO PRELHRC

Browse by classification

Community resources

courage is contagious

Viewing cable 04ANKARA1157, Pharmaceuticals Update: Multinationals

If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs

Understanding cables
Every cable message consists of three parts:
  • The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
  • The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
  • The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.
To understand the justification used for the classification of each cable, please use this WikiSource article as reference.

Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #04ANKARA1157.
Reference ID Created Released Classification Origin
04ANKARA1157 2004-02-27 11:34 2011-08-30 01:44 UNCLASSIFIED//FOR OFFICIAL USE ONLY Embassy Ankara
This record is a partial extract of the original cable. The full text of the original cable is not available.
UNCLAS SECTION 01 OF 05 ANKARA 001157 
 
SIPDIS 
 
 
DEPT FOR EB/TPP/MTA/IPC - SWILSON/JURBAN AND EUR/SE 
DEPT PASS USTR FOR LERRION/BPECK 
DEPT PASS LIBRARY OF CONGRESS 
DEPT PASS USPTO FOR ELAINE WU 
USDOC FOR ITA/MAC/DDEFALCO 
 
 
SENSITIVE 
 
 
E.O. 12958: N/A 
TAGS: ETRD KIPR TU
SUBJECT: Pharmaceuticals Update:  Multinationals 
Threatened by New Pricing Decree 
 
 
Ref:  Ankara 977 and previous 
 
 
Summary 
------- 
 
 
1. (SBU) U.S. companies have complained that a new GOT 
pricing caps threaten the commercial viability of many 
of their product lines, and could lead them to delay or 
suspend the launch of new pharmaceuticals in Turkey.  In 
a letter to USTR, the Foreign Trade Undersecretary 
maintains that the GOT views data exclusivity as an EU 
Customs Union obligation rather than a WTO TRIPS 
requirement, and that this policy will be introduced 
with an unspecified transition period.  The GOT's 
Council of State rendered a decision limiting the 
application of "cheapest generic" reimbursement policy 
in the state pension fund.  Embassy requests guidance on 
the pricing decree, and urges Washington agencies to 
pursue sustained engagement with the GOT on intellectual 
property and other WTO issues affecting the 
pharmaceuticals sector.  End Summary. 
 
 
New Price System A Blow to Research-Based Firms 
--------------------------------------------- -- 
 
 
2. (U) At a February 20 briefing for the Ambassador, 
U.S. companies expressed serious concern with a February 
14 pricing decree.  The decree, which is already in 
force, limits pharmaceuticals prices in Turkey to a 
maximum of 90 percent of the average of the lowest two 
prices prevailing in a group of five European countries. 
While the measure does not appear to address any 
intellectual property issues, it may contain WTO- 
inconsistent provisions allowing higher prices for 
domestically-produced generic drugs, and does not set 
objective pricing criteria or remedy mechanisms for 
companies applying under the decree (reproduced in para 
9). 
 
 
3. (U) Research-based companies had pressed for changes 
to the previous pricing system, which applied 
discriminatory price limits on imported pharmaceuticals, 
and had even suggested some forms of reference pricing. 
While the new system eliminates many of those 
provisions, research-based companies have told us that 
the new system will render sale of some medicines 
unprofitable, and could lead to delay or suspension in 
the launch of new molecules in Turkey.  AIFD, the 
Turkish research-based pharmaceuticals association, has 
written to the Prime Minister to register its concerns 
with the decree. 
 
 
4. (SBU) Econoff raised U.S. company concerns with 
Hayriye Mihcak, the Health Ministry's Director General 
for Pharmaceuticals, Dilek Emil, the Treasury 
Undersecretariat's Deputy Director General for Foreign 
Investment, and Husnu Dilemre, Foreign Trade's Deputy 
Director General for Multilateral Agreements.  All 
expressed some surprise that research-based companies 
did not consider the decree an improvement over the 
previous pricing system.  Foreign Trade told us that the 
Turkish decree was modeled on Portugese and Spanish drug 
pricing systems. 
 
 
 
 
Data Exclusivity 
---------------- 
 
 
5. (SBU) The GOT has not made an announcement on data 
exclusivity, though Mihcak told us that the Government 
planned to make an announcement on this by the end of 
March.  Dilemre also said that a decision on data 
exclusivity would be announced soon, but emphasized that 
Turkey viewed this as an EU Customs Union obligation 
rather than a WTO TRIPS requirement.  In a February 11 
letter to A/USTR Novelli (reproduced in para 10), 
Foreign Trade Undersecretary Tuncer Kayalar also made 
these points, but argued that Turkey would need a 
transition period for implementation. 
 
 
Legal Challenge on Reimbursement Policy 
--------------------------------------- 
 
 
6. (U) In January 2004, the Council of State (Danistay) 
issued a ruling restricting application of the "cheapest 
generic" pharmaceuticals reimbursement policy for the 
GOT's pension fund.  The decision, a preliminary 
injunction, calls for the GOT to stop implementation, 
within 30 days, of "cheapest generic" reference pricing. 
However, industry sources have said that the injunction 
is likely to be overturned as the case moves through the 
courts.  The Danistay also limited reimbursement of 
generics to those which the GOT has certified as 
"bioequivalent" with the brand name molecule.  While 
research-based companies have welcomed the decision, the 
impact will be limited:  industry sources relate that 
there is now a bioequivalent generic for most original 
drugs. 
 
 
Comment/Action Request 
---------------------- 
 
 
7. (SBU) Research-based industry is alarmed by the new 
pricing decree, though its concerns seem to lie more 
with the pricing formula for brand name drugs than with 
the parts of the decree (generic pricing, transparency) 
that could be WTO-inconsistent.  Embassy requests 
Washington agencies' guidance on whether to advocate for 
change in the pricing formula. 
 
 
8. (SBU) As noted reftel, elevating Turkey in the 
Special 301 Watch List system, combined with sustained 
Washington engagement, is our best hope for prodding the 
GOT to action on data exclusivity and WTO-inconsistent 
practices.  We understand that Commerce A/S Lash and 
Senator Lugar plan to write to top GOT officials on 
pharmaceuticals issues.  Embassy continues to recommend 
that Washington agencies also consider dispatching an 
interagency IPR delegation to Ankara, and sending 
additional high-level correspondence on these issues, 
and particularly to rebut the GOT's position that the 
TRIPS Agreement does not require data exclusivity. 
 
 
9. (U) Begin Text - AIFD Translation of GOT Pricing 
Decree: 
 
 
Decision No: 2004/6781 
It has been decided to enforce the attached "Decision 
Regarding the Pricing of Medicinal Product for Human 
Use" upon the letter dated 21/1/2004 and 003149 of the 
Ministry of Health, by the Council of Ministers on 
6/2/2004. 
 
 
Decision Regarding the Pricing of Medicinal Products for 
Human Use 
 
 
Article 1 - In accordance with "the Law no. 1262 on 
Pharmaceutical and Medicinal Products" and "the 
Fundamental Law no. 3359 on Healthcare Services", the 
Ministry of Health (the Ministry) shall determine the 
maximum prices by adopting the necessary measures that 
will be taken to ensure the affordability of medicinal 
products for human use (products).  Companies may 
request prices below the maximum price. The price 
approved by the Ministry of Health shall be in effect as 
of the date of its approval. 
 
 
Article 2 - The Ministry of Finance shall be authorized 
to investigate the suitability of these prices to the 
principles set forth in this Decision. 
 
 
Article 3- The maximum price of original products, 
excluding VAT, shall be determined as follows: 2 
reference countries with the cheapest prices of the 
product for which a price is to be determined in Turkey 
shall be selected out of 5 countries, namely France, 
Italy, Spain, Portugal and Greece in the year 2004 and 
to be deemed as suitable among the European Union (EU) 
countries by the Ministry; the retailer sale price of 
the product shall be determined by taking as basis 
maximum 90 percent of the average ex-factory price 
(sales price to the wholesalers calculated by deducting 
pharmacy and wholesaler profits from the retailer sale 
price) of these 2 reference countries and by adding the 
profit rates of wholesalers and pharmacies to be 
calculated in accordance with article 10. Should the ex- 
factory price in the country from where the product is 
imported be lower than the determined reference price, 
the profit rates of wholesalers and pharmacies shall be 
added to the price in the country from where it is 
imported. 
 
 
Article 4 - The retailer sales price of generic 
products, excluding VAT, shall be determined by taking 
as basis maximum 70 percent of the average of the ex- 
factory sales price of the original drugs of these 
products, calculated in accordance with article 3 and 
adding the profit rates of wholesalers and pharmacies. 
Yet, the maximum rate may be increased to 80 percent in 
case it is documented that locally manufactured raw 
materials have been utilized as the active ingredient of 
the drug in the production of generic products. In case 
the ex-factory sales price in the country from where the 
product is imported, results to be lower than the price 
determined for the EU countries, the profit rates of the 
wholesaler and pharmacies shall be added to the price in 
the pertinent country. 
 
 
Article 5 - The price of the products not marketed 
outside Turkey and the products not marketed by the EU 
countries shall be determined by taking into 
consideration the principles and the cost factors set 
forth in articles 3 and 4, provided it does not surpass 
the price of similar products. 
 
 
Article 6 - The ex-factory price of the products packed 
for hospitals shall be determined by taking into 
consideration the principles and the cost factors set 
forth in articles 3 and 4, provided it remains at least 
10percent below the unit prices of the original 
products. 
 
 
Article 7 - A "Price Evaluation Commission" shall be 
established and convene on a quarterly basis upon the 
participation of the representatives of the Ministry of 
Finance, the State Planning Organization and the Turkish 
Treasury under the coordination of the Ministry of 
Health, in order to submit proposals  to the Ministry of 
Health for the increase, decrease, or freezing of the 
price of medicinal products. In case of a change of more 
than 5percent in the foreign exchange rate within a 
minimum period of 30 days, the Price Evaluation 
Commission shall convene on an extraordinary basis, upon 
the invitation of the Ministry of Health to re-evaluate 
the prices of products. The secretarial services of the 
commission in question shall be executed by the Ministry 
of Health. 
 
 
A "Reimbursement Commission" shall be established and 
convene once every 6 months upon the participation of 
the representatives of the Ministry of Health, the State 
Planning Organization and the Turkish Treasury, the 
Social Insurance Institution, Emekli Sandygy and Bad-Kur 
and upon consulting the views of civil society 
organizations, under the coordination of the Ministry of 
Health, in order to submit proposals to the pertinent 
ministries. The secretarial services of the commission 
in question shall be executed by the Ministry of Health. 
 
 
Article  8 - Product manufacturers and importers shall 
be obligated to document that their products are 
original or generic. Manufacturers and importers shall 
be obligated to submit to the Ministry the ex-factory 
prices in the reference countries together with their 
requests for obtaining, increasing or decreasing a 
price. The TL equivalent of the prices determined shall 
be calculated upon the foreign exchange sales rate of 
the Central Bank of the Turkish Republic. The price 
which is deemed suitable shall be approved by the 
Ministry within 10 working days. The justification for a 
price which is not deemed suitable shall be communicated 
by the Ministry to the concerned company within 10 
working days. The pricing transaction shall be executed 
within 90 working days upon the submission of the valid 
documentation by the concerned company. This period may 
be extended by 60 working days in case of accumulation 
of applications and in periods of heavy workload. In 
case of failure of the concerned companies to submit 
their valid documents, the price determined by the 
Ministry shall be retained valid. 
 
 
Article 9 - In case of a decrease of 5percent or more in 
the price of the original product in the reference 
countries, the company manufacturing or importing the 
product shall be obligated to apply to the Ministry 
within 30 days to obtain a new price. A second degree 
withdrawal transaction shall be implemented on the 
products for it is determined by the Ministry that no 
such notification has been made and the registration 
shall be suspended for a period three times longer than 
the period in which no notification has been made, 
including 30 days. The suspension transaction shall be 
annulled by issuing the new price at the end of this 
period. 
 
 
Article 10- The wholesaler and pharmacy profit rates to 
be implemented when determining the retailer sales 
price of products in accordance with article 3 and 4, 
shall be determined in segments as follows, for both 
imported and local products: 
 
 
Out of the sales price to wholesalers/Wholesaler 
(Percent)/Pharmacy (Percent): 
 
 
Part up to/including 10 million TL: 9, 25 
Part between 10 - 50 million TL: 8, 24 
Part between 50 - 100 million TL: 7, 23 
Part between 100 - 200 million TL: 4, 16 
Part above 200 million TL: 2, 10 
 
 
The Ministry of Health shall be authorized to review 
these rates by taking into consideration the annual 
wholesale price index of chemical products of the State 
Statistics Institute of the former year and the 
allocation of the total sales of medicinal products in 
the last 3 years. 
 
 
Article 11 - Product manufacturers and importers are 
obligated to adhere to the principles set forth in this 
Decision.  Legal action within the pertinent 
legislation shall be taken against those in violation 
of these principles. 
 
 
Article 12 - The Ministry shall be authorized to issue 
notifications with regard to the implementation of this 
Decision. 
 
 
Article 13 - The Council of Ministers Decision dated 
6/2/2002, with no. 2002/4331 has been revoked. 
 
 
Temporary Article l- As of the publication date of this 
Decision, the prices of registered products shall be re- 
determined in accordance with the principles set forth 
in this Decision. The concerned companies shall apply to 
the Ministry upon having compiled the necessary 
documents in accordance with this Decision, within 45 
days as of the publication date of the Decision, in 
order to establish a basis for the determination of the 
new prices.  The registrations of the products for which 
no application is submitted within this period shall be 
suspended until the application date. The sales prices 
excluding VAT, to be determined in accordance with this 
article, shall not surpass the price in TL, excluding 
VAT, on the date of this Decision for local products, 
and the amount in TL, excluding VAT, corresponding to 
the foreign exchange sales rate of the Central Bank of 
the Turkish Republic, on the application date for the 
product for imported products. 
 
 
Temporary Article 2- The prices of imported products 
shall be re-determined ex-officio by the Ministry over 
the foreign exchange sales rate of the Central Bank of 
the Turkish Republic on the publication date of this 
Decision. The new prices shall be retained valid as of 
the approval date. 
 
 
Article 14- This Decision shall be enforced as of its 
publication date. 
 
 
Article 15- This Decision shall be executed by the 
Council of Ministers. 
 
 
End Text - AIFD Translation of GOT Pricing Decree. 
 
 
10. (U) Begin Text - Foreign Trade U/S - USTR Letter 
 
 
February 11, 2004 
Ms. Catherine A. Novelli 
Assistant US-Trade Representative for 
Europe and the Mediterranean 
Dear Ms. Novelli, 
 
 
I would like to thank you for your letter dated January 
14, 2004 which has provided me with the opportunity to 
clarify the misconception about the compliance of 
Turkey's IPR legislation with the TRIPS Agreement. 
 
 
As you will recall, the WTO Members unanimously 
confirmed the consistency of Turkey's IPR legislation 
and implementations with the TRIPS Agreement at the 
TRIPS Council's meeting in Geneva on November 30, 2000. 
 
 
Besides, as referred in your letter, our authorities are 
working on a plan to introduce and implement rules and 
regulations regarding data exclusivity in 
pharmaceuticals in line with our commitments arising 
from the Customs Union with the EU. 
 
 
As you may appreciate, this plan will not only have 
negative impacts on the consumers and the current public 
health policies but on the generic industry as well. 
Therefore, the transition period turns out to be a 
necessity to offset to a certain extent the economic and 
social pressures and to avoid any further economic 
damages that would be recovered at a higher cost 
otherwise. 
 
 
On the other hand, I would like to note that my 
colleagues are doing their best to figure out an option 
that keeps the transition period as short as possible. 
At this point, supportive approaches from our trading 
partners will certainly contribute to the early 
conclusion of their studies. 
 
 
Expressing my best wishes and highest regards to you, I 
remain, 
 
 
Sincerely Yours, 
 
 
Tuncer Kayalar 
Undersecretary 
 
 
End Text Foreign Trade/USTR Letter. 
Edelman